0001558370-24-008988.txt : 20240607 0001558370-24-008988.hdr.sgml : 20240607 20240607083029 ACCESSION NUMBER: 0001558370-24-008988 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRADIMED CORP CENTRAL INDEX KEY: 0001325618 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 731408526 STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36534 FILM NUMBER: 241027457 BUSINESS ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 BUSINESS PHONE: 4076778022 MAIL ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 8-K 1 irmd-20240605x8k.htm 8-K
0001325618false00013256182024-06-052024-06-05

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 5, 2024

IRADIMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

​

001-36534

    

73-1408526

(Commission File Number)

 

(IRS Employer Identification No.)

​

​

1025 Willa Springs Dr., Winter Springs, FL

    

32708

(Address of principal executive offices)

 

(Zip Code)

​

(407) 677-8022

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class:

    

Trading Symbol

    

Name of each exchange on which registered:

Common stock, par value $0.0001

 

IRMD

 

NASDAQ Capital Market

​

​

​

​

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On June 5, 2024, IRADIMED CORPORATION, a Delaware corporation (the “Company”), received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of the Company’s common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective as of the open of business on June 14, 2024. The Company’s common stock will continue to trade under the symbol “IRMD”. The Nasdaq Global Market operates in substantially the same manner as the Nasdaq Capital Market and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements.

Item 7.01. Regulation FD Disclosure.

On June 7, 2024, the Company issued a press release announcing that effective on the opening of business on June 14, 2024, the Company’s common stock will be uplisted to the Nasdaq Global Market. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

​

​

​

Exhibit No.

   

Description

99.1

​

Press release issued by the registrant on June 7, 2024.

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

IRADIMED CORPORATION

Date: June 7, 2024

​

​

​

​

By:

/s/John Glenn

​

Name:

John Glenn

​

Title:

Chief Financial Officer

​

​

​

​

 EX-99.1 2 irmd-20240605xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

​

IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market

Trading to commence effective on the market open June 14, 2024

​

Winter Springs, Florida, June 7, 2024 – IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.” Stockholders are not required to take any action due to the uplisting.

Roger Susi, President and Chief Executive Officer of Iradimed, expressed his enthusiasm about this significant achievement: “Iradimed’s advancement to the Nasdaq Global Market is a notable accomplishment for our company and reflects Iradimed’s continued growth trajectory and its dedication to delivering value to stockholders. With its higher listing standards, The Nasdaq Global Market will enhance our visibility in the marketplace and is considered a mark of distinction and standing for qualified companies. Iradimed is honored to be in the class of these companies and excited to be exposed to a larger audience of potential new investors.”

Iradimed was previously listed on the Nasdaq Capital Market following its successful initial public offering in 2014. The Nasdaq Global Market, known for its stringent financial and liquidity requirements and high corporate governance standards, includes the common stock of approximately 1,450 companies.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices and accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

For more information, please visit www.iradimed.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue,” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Iradimed’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond Iradimed’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Iradimed’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Iradimed assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

​

​

Media Contact:

John Glenn

IRADIMED CORPORATION

(407) 677-8022

InvestorRelations@iradimed.com

 GRAPHIC 3 irmd-20240605xex99d1001.jpg GRAPHIC begin 644 irmd-20240605xex99d1001.jpg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end EX-101.SCH 4 irmd-20240605.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 irmd-20240605_lab.xml EX-101.LAB EX-101.PRE 6 irmd-20240605_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 05, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2024
Entity File Number 001-36534
Entity Registrant Name IRADIMED CORPORATION
Entity Central Index Key 0001325618
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 73-1408526
Entity Address, Address Line One 1025 Willa Springs Dr.
Entity Address, City or Town Winter Springs
Entity Address State Or Province FL
Entity Address, Postal Zip Code 32708
City Area Code 407
Local Phone Number 677-8022
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol IRMD
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://iradimed.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports irmd-20240605.xsd irmd-20240605_lab.xml irmd-20240605_pre.xml irmd-20240605x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "irmd-20240605x8k.htm": { "nsprefix": "irmd", "nsuri": "http://iradimed.com/20240605", "dts": { "schema": { "local": [ "irmd-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "irmd-20240605_lab.xml" ] }, "presentationLink": { "local": [ "irmd-20240605_pre.xml" ] }, "inline": { "local": [ "irmd-20240605x8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://iradimed.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_6_5_2024_To_6_5_2024_23ilbIZMZ0WRnpS4s4uorg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240605x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_5_2024_To_6_5_2024_23ilbIZMZ0WRnpS4s4uorg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240605x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001558370-24-008988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-008988-xbrl.zip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irmd-20240605x8k_htm.xml IDEA: XBRL DOCUMENT 0001325618 2024-06-05 2024-06-05 0001325618 false 8-K 2024-06-05 IRADIMED CORPORATION DE 001-36534 73-1408526 1025 Willa Springs Dr. Winter Springs FL 32708 407 677-8022 false false false false false Common stock, par value $0.0001 IRMD NASDAQ